Washington, DC - May 11, 2009 — North Carolina leaders in personalized medicine will describe their successes and challenges today at “Personalized Medicine in North Carolina: Innovation to Application,” a conference hosted jointly by the Personalized Medicine Coalition and the North Carolina Biotechnology Center.

Many observers see personalized medicine, in which patients receive individualized treatment based on their molecular makeup, as facilitating the future of medicine, and North Carolina is a key center for this emerging field.

Among the speakers at today’s event are: Victor Dzau, MD, CEO, Duke University; Geoffrey S. Ginsburg, M.D., Ph.D., Director, Center for Genomic Medicine, Duke Institute for Genome Sciences & Policy; Vincent C. Henrich, PhD, Director for Center for Biotechnology, Genomics, and Health Research, UNC-Greensboro/Moses Cone-Guilford County Genomic Health Initiative; David King, CEO, LabCorp; Michael Murphy, MSc, CEO, ParagonDx; and Ralph Snyderman, MD, chancellor emeritus, Duke University. The conference was organized by Michael Stocum, MS, managing director of Personalized Medicine Partners.

The event also marks the release of a new edition of The Case for Personalized Medicine, the signature document of the Personalized Medicine Coalition. The report outlines the demonstrated benefits of personalized medicine and describes the pathway for its widespread adoption to improve healthcare.

Contact:
Elizabeth Schwinn (eschwinn@personalizedmedicinecoalition.org)
Communications Director
Personalized Medicine Coalition
(202) 589-1770

About the Personalized Medicine Coalition
The Personalized Medicine Coalition (PMC), representing a broad spectrum of academic, industrial, patient, provider, and payer communities, seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. For more information on the Personalized Medicine Coalition, please visit www.PersonalizedMedicineCoalition.org.